Saturday, November 14, 2015 9:32:42 AM
I suspect Northern Trust knows much more about the global potential of PS Targeting than their current holdings reveal. They were buyers back in 2006 back when the potential is UNKNOWN to many but known to a few
-----------
2006
Northern Trust Finally Updated...
added 802,990 shares, total holding now 1,396,045 shares.
I-Holding now 11.3%.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=14964190
-----------
2013
Maybe one day "Northern Trust" will find out about Peregrine Pharmaceuticals as well.
$5.2 Trillion under management and
http://www.northerntrust.com/about-northern-trust
William A. Osborn put in 39 years and ex-CEO of Northern Trust--- and sits on BOD of Abbott since 2008 till present.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=93556755
-----------
He serves on the Board of Directors of Northwestern Memorial HealthCare,
http://www.bloomberg.com/research/stocks/private/person.asp?personId=291898&privcapId=6521013
----------
I wonder if Dr. Parsa realized the potential of PS Targeting
http://www.feinberg.northwestern.edu/giving/docs/nm-philanthropist-august-2015.pdf
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1636864/
-----------
2006
Northern Trust Finally Updated...
added 802,990 shares, total holding now 1,396,045 shares.
I-Holding now 11.3%.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=14964190
-----------
2013
Maybe one day "Northern Trust" will find out about Peregrine Pharmaceuticals as well.
$5.2 Trillion under management and
http://www.northerntrust.com/about-northern-trust
William A. Osborn put in 39 years and ex-CEO of Northern Trust--- and sits on BOD of Abbott since 2008 till present.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=93556755
-----------
He serves on the Board of Directors of Northwestern Memorial HealthCare,
http://www.bloomberg.com/research/stocks/private/person.asp?personId=291898&privcapId=6521013
----------
I wonder if Dr. Parsa realized the potential of PS Targeting
http://www.feinberg.northwestern.edu/giving/docs/nm-philanthropist-august-2015.pdf
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1636864/
"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline." -- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!
